Cleared Traditional

K860143 - URINE DILUENT-FOR USE WITH ION SELECTIVE ELECTRODE (FDA 510(k) Clearance)

Class I Chemistry device.

K860143 · Reagent Laboratory, Inc. · Chemistry device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Feb 1986
Decision
26d
Days
Class 1
Risk

K860143 is an FDA 510(k) clearance for the URINE DILUENT-FOR USE WITH ION SELECTIVE ELECTRODE. Classified as Electrode, Ion Selective (non-specified) (product code JJP), Class I - General Controls.

Submitted by Reagent Laboratory, Inc. (Louisville, US). The FDA issued a Cleared decision on February 10, 1986 after a review of 26 days - a notably fast clearance cycle.

This device falls under the Chemistry FDA review panel, regulated under 21 CFR 862.2050 - the FDA in vitro diagnostics and chemistry framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Fast-track predicate clearance. Standard predicate reliance. The short review cycle indicates strong predicate alignment - the FDA found sufficient equivalence without extended technical review.

View all Reagent Laboratory, Inc. devices

Submission Details

510(k) Number K860143 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received January 15, 1986
Decision Date February 10, 1986
Days to Decision 26 days
Submission Type Traditional
Review Panel Chemistry (CH)
Summary -
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
62d faster than avg
Panel avg: 88d · This submission: 26d
Pathway characteristics
Predicate-based equivalence.

Device Classification

Product Code JJP Electrode, Ion Selective (non-specified)
Device Class Class 1 - General Controls
CFR Regulation 21 CFR 862.2050
What this classification means

Class I devices are subject to general controls only and most are exempt from 510(k) premarket notification. They represent the lowest regulatory burden in the FDA device framework.